initial antibody or its fragment u0430u043du0442u0438u0433u0435u043du0441u0432u044fu0437u044bu0432u0430u044eu0449u0438u0439 (options), the u043fu043eu043bu0438u043du0443u043au043bu0435u043eu0442u0438u0434 (options), the polypeptide (options), cell hostcomposition (variants) and a method of treatment of cns disease or animal organism (options)

摘要

endogenous Sp35 is a negative regulator u0430u043au0441u043eu043du043eu0432 neuron survival, regeneration, differentiation u043eu043bu0438u0433u043eu0434u0435u043du0434u0440u0438u0442u043eu0432 and u043cu0438u0435u043bu0438u043du0438u0437u0430u0446u0438u0438.molecules that block endogenous Sp35 function such as antibodies to Sp35, can be used as medicines for the treatment of u0434u0438u0441u0444u0443u043du0446u0438u0438 neurons and u043eu043bu0438u0433 u043eu0434u0435u043du0434u0440u0438u0442u043eu0432.the present invention provides antibodies specific for Sp35, and uses the data as a function of antibody antagonists of endogenous Sp35.the invention further provides u0433u0438u0431u0440u0438u0434u043eu043cu0443 and specific monoclonal antibodies isolated from u0444u0430u0433u043eu0432u043eu0439 nucleic acid libraries for data an. u0442u0438u0442u0435u043bu0430, and vectors and host cells.with these antibodies.in addition, the invention provides methods to stimulate the survival u043eu043bu0438u0433u043eu0434u0435u043du0434u0440u0438u0442u043eu0432 and u043cu0438u0435u043bu0438u043du0438u0437u0430u0446u0438u044e and vertebrates.including introduction to the treatment effective amount of antibodies to Sp35 spine.